Scinai Immunotherapeutics (SCNI) Liabilities and Shareholders Equity (2017 - 2025)

Scinai Immunotherapeutics has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $19.6 billion for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $19.6 billion, up 145468.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $19.6 billion (up 33944.8% YoY), and the FY2025 annual result was $19.6 billion, up 145468.11% from the prior year.
• Liabilities and Shareholders Equity came in at $19.6 billion for Q4 2025 at Scinai Immunotherapeutics, up from $11.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $19.6 billion in Q4 2025 to a low of $11.8 million in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $19.9 million (2023), against an average of $1.3 billion.
• Across the five-year window, Liabilities and Shareholders Equity sank 35.45% in 2023 and soared 145468.11% in 2025, its largest moves.
• Scinai Immunotherapeutics' Liabilities and Shareholders Equity stood at $32.0 million in 2021, then dropped by 15.51% to $27.1 million in 2022, then plunged by 35.45% to $17.5 million in 2023, then dropped by 23.03% to $13.4 million in 2024, then jumped by 145468.11% to $19.6 billion in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $19.6 billion (Q4 2025), $11.8 million (Q2 2025), and $13.4 million (Q4 2024), per Business Quant data.